| scholarly article | Q13442814 |
| P50 | author | Teresa Latham | Q56800266 |
| Juliana N Anyanwu | Q96177127 | ||
| Olatundun Williams | Q96177128 | ||
| Casey L Sautter | Q96177129 | ||
| Heather Hume | Q96177130 | ||
| Christopher Ndugwa | Q96177157 | ||
| Phillip Kasirye | Q42853043 | ||
| Robert O Opoka | Q56784770 | ||
| Russell E Ware | Q56785312 | ||
| Chandy C. John | Q56785321 | ||
| P2093 | author name string | Heather Hume | |
| Casey L Sautter | |||
| Christopher Ndugwa | |||
| Juliana N Anyanwu | |||
| Olatundun Williams | |||
| Phillip Kasirye | |||
| P2860 | cites work | Quality of parental consent in a Ugandan malaria study | Q56919137 |
| Ethical and scientific implications of the globalization of clinical research | Q58670198 | ||
| Consent for Participation in the Bloemfontein Vitamin A Trial: How Informed and Voluntary? | Q62576698 | ||
| Hydroxyurea induces the gene expression and synthesis of proinflammatory cytokines in vivo | Q71975537 | ||
| Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group | Q78225104 | ||
| Clinical trials and medical care: defining the therapeutic misconception | Q21144663 | ||
| Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase | Q24554376 | ||
| Inherited haemoglobin disorders: an increasing global health problem | Q24653670 | ||
| Protection afforded by sickle-cell trait against subtertian malareal infection | Q24671995 | ||
| Aspects of vulnerable patients and informed consent in clinical trials | Q26825445 | ||
| Ethical issues in the export, storage and reuse of human biological samples in biomedical research: perspectives of key stakeholders in Ghana and Kenya | Q28654359 | ||
| Inhaled nitric oxide reduces endothelial activation and parasite accumulation in the brain, and enhances survival in experimental cerebral malaria | Q28742640 | ||
| Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia | Q33819687 | ||
| A role for fetal hemoglobin and maternal immune IgG in infant resistance to Plasmodium falciparum malaria | Q33885842 | ||
| Quality of informed consent in cancer clinical trials: a cross-sectional survey | Q34104151 | ||
| Sickle-cell disease | Q34153339 | ||
| Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia | Q34308407 | ||
| Ethical and legal constraints to children's participation in research in Zimbabwe: experiences from the multicenter pediatric HIV ARROW trial | Q34346519 | ||
| Assessing the quality of informed consent in a resource-limited setting: a cross-sectional study | Q34385745 | ||
| Update on the use of hydroxyurea therapy in sickle cell disease | Q34737460 | ||
| Differential modulation of adhesion molecule expression by hydroxycarbamide in human endothelial cells from the micro- and macrocirculation: potential implications in sickle cell disease vasoocclusive events | Q34750534 | ||
| High mortality from Plasmodium falciparum malaria in children living with sickle cell anemia on the coast of Kenya | Q34776013 | ||
| Nitric oxide protection against murine cerebral malaria is associated with improved cerebral microcirculatory physiology | Q34833840 | ||
| Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). | Q35097294 | ||
| Informed consent: study of quality of information given to participants in a clinical trial | Q35180937 | ||
| Hydroxyurea for sickle cell anemia: what have we learned and what questions still remain? | Q35234959 | ||
| Tumor necrosis factor-alpha expression in the brain during fatal murine cerebral malaria: evidence for production by microglia and astrocytes. | Q35764305 | ||
| Correlation between enhanced vascular permeability, up-regulation of cellular adhesion molecules and monocyte adhesion to the endothelium in the retina during the development of fatal murine cerebral malaria | Q35782432 | ||
| An approach to evaluating the therapeutic misconception | Q35989895 | ||
| Nitric oxide in Tanzanian children with malaria: inverse relationship between malaria severity and nitric oxide production/nitric oxide synthase type 2 expression | Q36367170 | ||
| Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates | Q36540250 | ||
| Evidence of Endothelial Activation in Asymptomatic Plasmodium falciparum Parasitemia and Effect of Blood Group on Levels of von Willebrand Factor in Malaria | Q36851146 | ||
| Factors that influence parental decisions to participate in clinical research: consenters vs nonconsenters. | Q36906502 | ||
| Sickle cell disease in Africa: a neglected cause of early childhood mortality | Q37001823 | ||
| Bacteraemia in Kenyan children with sickle-cell anaemia: a retrospective cohort and case-control study | Q37402261 | ||
| "It's my blood": ethical complexities in the use, storage and export of biological samples: perspectives from South African research participants | Q37539610 | ||
| Mindsets, informed consent, and research | Q37700964 | ||
| Systematic review of current and emerging strategies for reducing morbidity from malaria in sickle cell disease | Q38074184 | ||
| Emerging science of hydroxyurea therapy for pediatric sickle cell disease | Q38164192 | ||
| Hydroxyurea therapy for sickle cell anemia | Q38586282 | ||
| Effects of vector-control interventions on changes in risk of malaria parasitaemia in sub-Saharan Africa: a spatial and temporal analysis | Q38861129 | ||
| Research on stored biological samples: the views of Ugandans. | Q38880815 | ||
| Fetal haemoglobin and malaria | Q39467147 | ||
| A pilot study of hydroxyurea to prevent chronic organ damage in young children with sickle cell anemia. | Q41734468 | ||
| Nitric oxide donor properties of hydroxyurea in patients with sickle cell disease | Q43883731 | ||
| Hydroxyurea downregulates endothelin-1 gene expression and upregulates ICAM-1 gene expression in cultured human endothelial cells. | Q43977840 | ||
| Plasma levels of TNF-alpha in sickle cell patients receiving hydroxyurea | Q44765608 | ||
| Altered levels of pro-inflammatory cytokines in sickle cell disease patients during vaso-occlusive crises and the steady state condition. | Q44805631 | ||
| Increased levels of soluble ICAM-1 in the plasma of sickle cell patients are reversed by hydroxyurea | Q44999407 | ||
| Increased adhesive properties of neutrophils in sickle cell disease may be reversed by pharmacological nitric oxide donation | Q46713968 | ||
| Editorial: Popular concerns about medical research projects in sub-Saharan Africa--a critical voice in debates about medical research ethics | Q47197299 | ||
| Cytokines and soluble adhesion molecules in sickle cell anemia patients during hydroxyurea therapy | Q47738528 | ||
| Tumor necrosis factor and disease severity in children with falciparum malaria | Q47892964 | ||
| Effects of hydroxyurea on malaria, parasite growth and adhesion in experimental models. | Q48036749 | ||
| Understanding of informed consent in a low-income setting: three case studies from the Kenyan Coast | Q48519507 | ||
| P433 | issue | 2 | |
| P921 | main subject | malaria | Q12156 |
| hydroxyurea | Q212272 | ||
| P304 | page(s) | e110 | |
| P577 | publication date | 2016-06-23 | |
| P1433 | published in | JMIR research protocols | Q27724721 |
| P1476 | title | Novel Use of Hydroxyurea in an African Region With Malaria: Protocol for a Randomized Controlled Clinical Trial | |
| P478 | volume | 5 |
| Q41676261 | Cell Cycle Inhibition To Treat Sleeping Sickness |
| Q38692796 | Hydroxyurea (hydroxycarbamide) for sickle cell disease. |
| Q37585014 | Sickle cell anemia in sub-Saharan Africa: advancing the clinical paradigm through partnerships and research. |
| Q52795486 | Sickle cell disease. |
| Q42374716 | Sickle cell disease: Status with particular reference to India |
Search more.